2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.
Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.
There is a trial of pembrolizumab (Keytruda) in combination with radiation, which might one day replace cisplatin, explains Weiss.
There is also a study investigating durvalumab (Imfinzi) with carboplatin and nab-paclitaxel (Abraxane) as induction chemotherapy prior to surgery for hard-to-cure patients, states Weiss.
Related Content: